Literature DB >> 16696827

Decrease in creatine kinase messenger RNA expression in the hippocampus and dorsolateral prefrontal cortex in bipolar disorder.

Matthew L MacDonald1, Alipi Naydenov, Melissa Chu, David Matzilevich, Christine Konradi.   

Abstract

OBJECTIVES: Bipolar disorder (BPD) affects more than 2 million adults in the USA and ranks among the top 10 causes of worldwide disabilities. Despite its prevalence, very little is known about the etiology of BPD. Recent evidence suggests that cellular energy metabolism is disturbed in BPD. Mitochondrial function is altered, and levels of high-energy phosphates, such as phosphocreatine (PCr), are reduced in the brain. This evidence has led to the hypothesis that deficiencies in energy metabolism could account for some of the pathophysiology observed in BPD. To further explore this hypothesis, we examined levels of creatine kinase (CK) mRNA, the enzyme involved in synthesis and metabolism of PCr, in the hippocampus (HIP) and dorsolateral prefrontal cortex (DLPFC) of control, BPD and schizophrenia subjects.
METHODS: Tissue was obtained from the Harvard Brain Tissue Resource Center. Real-time quantitative polymerase chain reaction (HIP, DLPFC) and gene expression microarrays (HIP) were employed to compare the brain and mitochondrial 1 isoforms of CK.
RESULTS: Both CK isoforms were downregulated in BPD. Furthermore, mRNA transcripts for oligodendrocyte-specific proteins were downregulated in the DLPFC, whereas the mRNA for the neuron-specific protein microtubule-associated protein 2 was downregulated in the HIP.
CONCLUSION: Although some of the downregulation of CK might be explained by cell loss, a more general mechanism seems to be responsible. The downregulation of CK transcripts, if translated into protein levels, could explain the reduction of high-energy phosphates previously observed in BPD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16696827      PMCID: PMC4208624          DOI: 10.1111/j.1399-5618.2006.00302.x

Source DB:  PubMed          Journal:  Bipolar Disord        ISSN: 1398-5647            Impact factor:   6.744


  53 in total

1.  Muscle creatine kinase isoenzyme expression in adult human brain.

Authors:  R J Hamburg; D L Friedman; E N Olson; T S Ma; M D Cortez; C Goodman; P R Puleo; M B Perryman
Journal:  J Biol Chem       Date:  1990-04-15       Impact factor: 5.157

2.  Creatine phosphokinase. Increased activity of the spinal fluid in psychotic patients.

Authors:  S Vale; M A Espejel; F Calcaneo; J Ocampo; J Diaz-de-Leon
Journal:  Arch Neurol       Date:  1974-01

3.  Recurrence pattern of serum creatine phosphokinase levels in repeated acute psychosis.

Authors:  I Manor; H Hermesh; A Valevski; Y Benjamin; H Munitz; A Weizman
Journal:  Biol Psychiatry       Date:  1998-02-15       Impact factor: 13.382

4.  31P-MRS study of acetyl-L-carnitine treatment in geriatric depression: preliminary results.

Authors:  Jay W Pettegrew; Joseph Levine; Samuel Gershon; Jeffrey A Stanley; David Servan-Schreiber; Kanagasabai Panchalingam; Richard J McClure
Journal:  Bipolar Disord       Date:  2002-02       Impact factor: 6.744

5.  Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder.

Authors:  G Rajkowska; A Halaris; L D Selemon
Journal:  Biol Psychiatry       Date:  2001-05-01       Impact factor: 13.382

Review 6.  Lactic acidosis and mitochondrial disorders.

Authors:  D S Kerr
Journal:  Clin Biochem       Date:  1991-08       Impact factor: 3.281

7.  Molecular evidence for mitochondrial dysfunction in bipolar disorder.

Authors:  Christine Konradi; Molly Eaton; Matthew L MacDonald; John Walsh; Francine M Benes; Stephan Heckers
Journal:  Arch Gen Psychiatry       Date:  2004-03

8.  Association of mitochondrial complex I subunit gene NDUFV2 at 18p11 with bipolar disorder.

Authors:  Shinsuke Washizuka; Chihiro Kakiuchi; Kanako Mori; Hiroshi Kunugi; Osamu Tajima; Tsuyoshi Akiyama; Shinichiro Nanko; Tadafumi Kato
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2003-07-01       Impact factor: 3.568

9.  Brain metabolic alterations in medication-free patients with bipolar disorder.

Authors:  Stephen R Dager; Seth D Friedman; Aimee Parow; Christina Demopulos; Andrew L Stoll; In Kyoon Lyoo; David L Dunner; Perry F Renshaw
Journal:  Arch Gen Psychiatry       Date:  2004-05

Review 10.  An overview of recent findings of the Stanley Foundation Bipolar Network (Part I).

Authors:  Robert M Post; Gabriele S Leverich; Lori L Altshuler; Mark A Frye; Trisha M Suppes; Paul E Keck; Susan L McElroy; Ralph Kupka; Willem A Nolen; Heinz Grunze; Jorg Walden
Journal:  Bipolar Disord       Date:  2003-10       Impact factor: 6.744

View more
  28 in total

1.  The effects of chronic treatment with mood stabilizers on the rat hippocampal post-synaptic density proteome.

Authors:  Dhaval Nanavati; Daniel R Austin; Lisa A Catapano; David A Luckenbaugh; Ayse Dosemeci; Husseini K Manji; Guang Chen; Sanford P Markey
Journal:  J Neurochem       Date:  2011-09-21       Impact factor: 5.372

2.  Decreased brain PME/PDE ratio in bipolar disorder: a preliminary (31) P magnetic resonance spectroscopy study.

Authors:  Xian-Feng Shi; Paul J Carlson; Young-Hoon Sung; Kristen K Fiedler; Lauren N Forrest; Tracy L Hellem; Rebekah S Huber; Seong-Eun Kim; Chun Zuo; Eun-Kee Jeong; Perry F Renshaw; Douglas G Kondo
Journal:  Bipolar Disord       Date:  2015-10-19       Impact factor: 6.744

3.  Fenproporex increases locomotor activity and alters energy metabolism, and mood stabilizers reverse these changes: a proposal for a new animal model of mania.

Authors:  Gislaine T Rezin; Camila B Furlanetto; Giselli Scaini; Samira S Valvassori; Cinara L Gonçalves; Gabriela K Ferreira; Isabela C Jeremias; Wilson R Resende; Mariane R Cardoso; Roger B Varela; João Quevedo; Emilio L Streck
Journal:  Mol Neurobiol       Date:  2013-10-15       Impact factor: 5.590

Review 4.  Mitochondrial Oxidative Phosphorylation System (OXPHOS) Deficits in Schizophrenia: Possible Interactions with Cellular Processes.

Authors:  Oded Bergman; Dorit Ben-Shachar
Journal:  Can J Psychiatry       Date:  2016-08       Impact factor: 4.356

5.  Abnormal high-energy phosphate molecule metabolism during regional brain activation in patients with bipolar disorder.

Authors:  C Yuksel; F Du; C Ravichandran; J R Goldbach; T Thida; P Lin; B Dora; J Gelda; L O'Connor; S Sehovic; S Gruber; D Ongur; B M Cohen
Journal:  Mol Psychiatry       Date:  2015-03-10       Impact factor: 15.992

6.  Structure-function associations in hippocampus in bipolar disorder.

Authors:  Lara G Chepenik; Fei Wang; Linda Spencer; Marisa Spann; Jessica H Kalmar; Fay Womer; E Kale Edmiston; Brian Pittman; Hilary P Blumberg
Journal:  Biol Psychol       Date:  2012-02-10       Impact factor: 3.251

7.  Human olfactory epithelial cells generated in vitro express diverse neuronal characteristics.

Authors:  K E Borgmann-Winter; N E Rawson; H-Y Wang; H Wang; M L Macdonald; M H Ozdener; K K Yee; G Gomez; J Xu; B Bryant; G Adamek; N Mirza; E Pribitkin; C-G Hahn
Journal:  Neuroscience       Date:  2008-10-17       Impact factor: 3.590

8.  Effects of the brain-derived neurotrophic growth factor val66met variation on hippocampus morphology in bipolar disorder.

Authors:  Lara G Chepenik; Carolyn Fredericks; Xenophon Papademetris; Linda Spencer; Cheryl Lacadie; Fei Wang; Brian Pittman; James S Duncan; Lawrence H Staib; Ronald S Duman; Joel Gelernter; Hilary P Blumberg
Journal:  Neuropsychopharmacology       Date:  2008-08-13       Impact factor: 7.853

Review 9.  Targeting mitochondrially mediated plasticity to develop improved therapeutics for bipolar disorder.

Authors:  Rafael T de Sousa; Rodrigo Machado-Vieira; Carlos A Zarate; Husseini K Manji
Journal:  Expert Opin Ther Targets       Date:  2014-07-24       Impact factor: 6.902

Review 10.  Mitochondrial involvement in psychiatric disorders.

Authors:  Ling Shao; Maureen V Martin; Stanley J Watson; Alan Schatzberg; Huda Akil; Richard M Myers; Edward G Jones; William E Bunney; Marquis P Vawter
Journal:  Ann Med       Date:  2008       Impact factor: 4.709

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.